麦斯莫医疗（MASI）今日盘前股价大涨38.19%，引起了市场的广泛关注。
消息面上，据英国《金融时报》等多家媒体报道，生命科学巨头丹纳赫（DHR）正接近达成一项价值近100亿美元的交易，以收购脉搏血氧仪制造商麦斯莫医疗。报道援引知情人士消息称，该交易最早可能于周二宣布，对麦斯莫医疗的估值较其近期约70亿美元的市值有显著溢价。
此次收购若达成，将是丹纳赫自2023年收购Abcam以来的首次重大收购，也将使其业务拓展至病人监测产品领域。麦斯莫医疗是患者监测技术的领先企业，以其血氧仪产品闻名，此前在与苹果公司的专利诉讼中获胜。市场分析认为，潜在的收购溢价是推动麦斯莫医疗股价在盘前交易中大幅上涨的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.